ClinicalTrials.gg
RecruitingNCT07764679Updated Aug 14, 2026

A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection

A Phase 3 interventional study of [18F]Fluorbetazine injection in Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), sponsored by HTA Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by HTA Co., Ltd. · Phase 3, Interventional, and Diagnostic

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 309 studies in Cognitive Dysfunction with a site in China — 143 open to participants now, 155 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Planned enrollment
21st of 190
400 · median 110
Started
2025
with 31 others
Phase 3
12 of 309
4 open now
Primary completion
2027-12
later than 104 of 154 live
Registered
231st of 309
by date

Among the 309 studies in Cognitive Dysfunction with a site in China, this one is the 21st largest by planned enrollment of the 190 interventional ones that give a count, is one of 32 that started in 2025, is one of 12 in phase 3, reaches primary completion later than 104 of the 154 other live ones, and was the 231st registered.

Cognitive Dysfunction

3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

143 of the 309 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 309 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

A multicenter phase III clinical study evaluating the diagnostic performance and safety of PET for the deposition of Aβ plaques in the brain of participants with normal cognitive function, MCI and AD using [18F]Fluorbetazine injection.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Alzheimer's Disease (AD)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1 1. Men or women aged ≥ 40 years (including the threshold age). 2. Men or women with fertility must use effective measures during the study period. Effective contraceptive measures include sterilization, intrauterine hormone devices, condoms, birth control pills, abstinence, or vasectomy.

3. Meet the diagnostic criteria for normal cognitive function, Mild Cognitive Impairment (MCI), or Alzheimer's disease (AD).

4. Participants voluntarily join the study, can cooperate with the experimental observations, and sign a written form. For participants with AD dementia, the informed consent form must be signed together with their legal guardian. If the participant is unable to sign the informed consent form due to limited cognitive ability or other reasons, the participant's signature space may be left blank, with the reason documented. The guardian should sign in the designated space for explanation.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to [18F]Fluorbetazine injection or its .
  2. Presence of previously implanted metal devices that are incompatible with MRI examinations, including pacemakers, defibrillators, insulin pumps, cochlear implants, intraocular metal implants, nerve stimulators, or CNS aneurysm clips; or suffering from claustrophobia or intolerance to imaging procedures for other reasons.
  3. Cognitive impairment caused by reasons other than Alzheimer's disease (AD).
  4. Cranial MRI scan shows one or more of the following results:

    • More than 2 infarctions with a diameter greater than 2 cm in any part of the brain;
    • Infarctions of any diameter in key areas such as the thalamus, hippocampus, entorhinal cortex, hippocampal gyrus, gyrus, cortex, or other subcortical gray matter nuclei;
    • Fazekas Scale grading of white matter lesions > 2;
    • Presence of brain tumors, intracranial infections, or cerebral hemorrhage, and deemed unsuitable for participation in this study by the researchers.
  5. Current psychiatric illnesses, such as severe depression or schizophrenia, based on medical history, and the researchers have assessed that the imaging process cannot be completed. Researchers should carefully consider whether participants with dementia and behavioral disorders who may require psychiatric medication can complete the imaging process.
  6. Received radiopharmaceutical imaging or treatment within at least 5 half-lives prior to screening.
  7. Suffering from other serious and/or poorly controlled and/or unstable diseases, and deemed unsuitable for participation in this study by the researcher.
  8. Positive test results for (HIV) antibodies or Treponema pallidum antibodies.
  9. History of alcohol or drug abuse.
  10. Pregnant or lactating women with positive pregnancy test results during the screening period (including premenopausal women who have not undergone surgical sterilization and women within one year after menopause).
  11. Participated in any clinical trials within 4 weeks prior to enrollment and used drugs; or those who plan to participate in any clinical trials during the study period.
  12. Other situations deemed unsuitable for participating in this clinical trial by the researchers.

Participants with Normal Cognitive Function

1. Any evidence suggesting the possibility of AD from previous MRI, CT, or other biomarker studies.

MCI and AD Dementia Participants

  1. Received anti-Aβ targeted therapy drugs, such as lecanemab monoclonal antibody, or treated or prophylactic anti-Aβ vaccines.
  2. Suffering from neurodegenerative diseases other than AD, including but not limited to Parkinson's disease, Pick's disease, frontotemporal degeneration (FTLD), Huntington's disease, Down syndrome, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or progressive supranuclear palsy (PSP).
  3. Previously or currently diagnosed with dementia other than AD, including but not limited to Parkinson's disease dementia, Lewy body dementia, frontotemporal dementia, vascular dementia, mixed dementia, etc.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    using [18F]Fluorbetazine injection.

    Drug: [18F]Fluorbetazine injection

Interventions

  • Drug[18F]Fluorbetazine injection

    normal cognitive function, mild cognitive impairment (MCI) caused by Alzheimer's disease (AD) using \[18F\]Fluorbetazine injection.

06

What researchers measure

Primary outcomes

  1. The sensitivity and specificity of PET imaging visual interpretation results compared to true standards after a single intravenous injection of [18F]Fluorbetazine injection in participants with AD induced MCI, AD dementia and normal cognitive.

    The sensitivity and specificity of PET imaging visual interpretation results compared to true standards after a single intravenous injection of \[18F\]Fluorbetazine injection in participants with AD induced MCI, AD dementia and normal cognitive.

    Time frame: 1 year

Secondary outcomes

  1. 1 Calculate and compare the standard uptake value ratio (SUVR) of cortical target areas (lateral temporal lobe, frontal lobe, posterior cingulate gyrus/anterior cingulate cortex, and parietal lobe) relative to the cerebellum between AD derived MCI/AD dem

    1 Calculate and compare the standard uptake value ratio (SUVR) of cortical target areas (lateral temporal lobe, frontal lobe, posterior cingulate gyrus/anterior cingulate cortex, and parietal lobe) relative to the cerebellum between AD derived MCI/AD dementia participants and cognitively normal participants, and determine the diagnostic performance of SUVR;

    Time frame: 1year

  2. 2 Using Kappa coefficient to compare the consistency of visual analysis of PET imaging among independent readers, within readers, and overall

    2 Using Kappa coefficient to compare the consistency of visual analysis of PET imaging among independent readers, within readers, and overall

    Time frame: 1year

  3. 3 Calculate the cerebral gray matter to white matter SUV ratio (GWR) on PET images of AD derived MCI/AD dementia participants and cognitively normal participants, and evaluate image features.

    3 Calculate the cerebral gray matter to white matter SUV ratio (GWR) on PET images of AD derived MCI/AD dementia participants and cognitively normal participants, and evaluate image features.

    Time frame: 1year

Other outcomes

  1. The safety assessment is based on serious adverse events, adverse events

    Serious adverse events and adverse events during the research period;

    Time frame: From the first day of application to one week after administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individualized patient data needs to be kept confidential

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 49 phase 3 interventional studies under Cognitive Dysfunction, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 63. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Aug 14, 2026
StartActual
Jun 20, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07764679
Lead sponsor
HTA Co., Ltd.
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Jun 20, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 14, 2026

Study contacts

Xiaomin Xu, Master
Contact
xuxiaomin@circ.com.cn
010-69357316

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion